In a startup ecosystem often buzzing with consumer tech headlines, Leumas is building something very different—quietly, methodically, and with deep conviction. The Bengaluru-based deeptech manufacturing startup has just raised $2.2 million in a seed funding round led by Capital 2B, the deeptech fund backed by Info Edge and Temasek, with additional support from Capital-A and Anicut Capital.
But this isn’t just another funding announcement. It’s the story of a company that’s reimagining how products get made—at the most fundamental level.
We sat down with Subhajit Biswas and Nitesh K, co-founders of Leumas, to understand what “on-demand manufacturing” really looks like—and why the future of production may not involve massive, traditional factories at all.
“Our vision is simple,” says Subhajit, “Can we bring the same agility, customization, and intelligence that’s now standard in software—into the world of physical products?”
At the heart of Leumas is a bold idea: modular, cyber-physical factories powered by AI-driven robotics and vision-based quality systems. Think of it as Factory-as-a-Service, built from the ground up for wellness and pharma brands who need flexibility, precision, and speed—but without the capital drain of traditional setups.
Their modular micro-factories are fully software-defined, which means they can scale and adapt faster than legacy plants. That’s no small feat in a sector where compliance, quality, and consistency can make or break a brand.
In fact, Leumas has already co-developed and scaled over 120 products in the past year, working closely with wellness brands across India, the US, and MENA. Now, with fresh capital, the startup plans to expand its R&D, deploy dedicated modular factories, and move from pilot to production at scale.
“It’s not about replacing people,” Nitesh adds. “It’s about enabling smarter production. We’re here to make manufacturing accessible, efficient, and future-ready.”
The team has also inked partnerships with major pharma and food research institutions to build compliant, scalable production capacities using their factory modules.
As the outsourced development and manufacturing market for wellness and pharma inches toward a projected $400 billion by 2030, Leumas believes its tech-driven, adaptive approach positions it well to serve a growing base of global customers.
And for an industry that often feels stuck in the past, Leumas might just be the quiet disruptor it didn’t know it needed.
